Novo Nordisk A/S Sponsored ADR logo

Novo Nordisk A/S Sponsored ADR (0TDD)

Market Open
8 Aug, 15:30
LSE LSE
$
50. 42
+1.68
+3.45%
$
- Market Cap
48.26 P/E Ratio
2.05% Div Yield
207,771 Volume
0 Eps
$ 48.74
Previous Close
Day Range
49.15 51.09
Year Range
44.97 140
Want to track 0TDD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 86 days

Summary

0TDD trading today higher at $50.42, an increase of 3.45% from yesterday's close, completing a monthly increase of 6.94% or $3.27. Over the past 12 months, 0TDD stock lost -41.79%.
0TDD pays dividends to its shareholders, with the most recent payment made on Apr 08, 2025. The next announced payment will be in In 2 weeks on Aug 26, 2025 for a total of $0.41192.
The last earnings report, released on Aug 06, 2025, missed the consensus estimates by -0.04%. On average, the company has surpassed earnings expectations by 1.86%, based on the last three reports. The next scheduled earnings report is due on Nov 05, 2025.
Novo Nordisk A/S Sponsored ADR has completed 5 stock splits, with the recent split occurring on Sep 20, 2023.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NYSE (USD).

0TDD Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities

Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities

I invest for long-term total return, prioritizing dividend growth and quality companies trading at bargain valuations, especially during industry downturns. Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. My quantitative screen highlights six pharma leaders, with Novo Nordisk (NVO) and Merck (MRK) scoring highest across dividends, growth, capital structure, and free cash flow.

Seekingalpha | 40 minutes ago
Why I Tripled My Novo Nordisk Position

Why I Tripled My Novo Nordisk Position

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages. Despite lowered 2025 guidance and slower growth, core products Ozempic and Wegovy continue to deliver impressive sales and global expansion opportunities. Heavy capital expenditures are temporary, aimed at expanding manufacturing to meet strong demand; long-term free cash flow margins should recover.

Seekingalpha | 1 day ago
Novo Nordisk: This Won't Last

Novo Nordisk: This Won't Last

Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum. The valuation is attractive relative to historical metrics, with a +3% yield and significant room for capital appreciation as demand continues to outpace supply.

Seekingalpha | 2 days ago

Novo Nordisk A/S Sponsored ADR Dividends

Novo Nordisk A/S Sponsored ADR logo
NVO In 1 week
Announced
Semi Annual
$0.41 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 4 months ago
Paid
Other
$1.1 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 11 months ago
Paid
Other
$0.52 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 22 Mar 2024
Paid
Other
$0.93 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 18 Aug 2023
Paid
Other
$0.44 Per Share

Novo Nordisk A/S Sponsored ADR Earnings

5 Nov 2025 (In 2 months) Date
5.86
Cons. EPS
-
EPS
5 Nov 2025 (In 2 months) Date
0.99
Cons. EPS
-
EPS
6 Aug 2025 Date
6
Cons. EPS
5.96
EPS
7 May 2025 Date
0.92
Cons. EPS
6.53
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
Novo Nordisk A/S Sponsored ADR logo
NVO In 1 week
Announced
Semi Annual
$0.41 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 4 months ago
Paid
Other
$1.1 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 11 months ago
Paid
Other
$0.52 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 22 Mar 2024
Paid
Other
$0.93 Per Share
Novo Nordisk A/S Sponsored ADR logo
NVO 18 Aug 2023
Paid
Other
$0.44 Per Share
5 Nov 2025 (In 2 months) Date
5.86
Cons. EPS
-
EPS
5 Nov 2025 (In 2 months) Date
0.99
Cons. EPS
-
EPS
6 Aug 2025 Date
6
Cons. EPS
5.96
EPS
7 May 2025 Date
0.92
Cons. EPS
6.53
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS

Novo Nordisk A/S Sponsored ADR (0TDD) FAQ

What is the stock price today?

The current price is $50.42.

On which exchange is it traded?

Novo Nordisk A/S Sponsored ADR is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0TDD.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.05%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 5.86.

When is the next earnings date?

The next earnings report will release on Nov 05, 2025.

Has Novo Nordisk A/S Sponsored ADR ever had a stock split?

Novo Nordisk A/S Sponsored ADR had 5 splits and the recent split was on Sep 20, 2023.

Novo Nordisk A/S Sponsored ADR Profile

Drug Manufacturers - General Industry
Healthcare Sector
Lars Fruergaard Jorgensen CEO
LSE Exchange
US6701002056 ISIN
DK Country
77,406 Employees
18 Aug 2025 Last Dividend
20 Sep 2023 Last Split
- IPO Date

Overview

Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.

Products and Services

Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:

  • Diabetes and Obesity Care: This segment includes products specifically designed to manage diabetes and obesity, along with related cardiovascular conditions and other emerging therapeutic areas. The company’s commitment to combating diabetes and obesity is reflected in its continuous pursuit of safer and more effective treatments.
  • Rare Disease: Novo Nordisk takes a targeted approach to rare diseases, focusing on rare blood disorders, rare endocrine disorders, and providing hormone replacement therapy. These specialized treatments are developed with the aim of addressing medical needs that are often underserved, demonstrating the company's dedication to all patients, regardless of the rarity of their condition.
  • Insulin Pens: The company produces a variety of insulin pens that are designed for ease of use, ensuring that patients can manage their condition with confidence and precision. These devices are a testament to Novo Nordisk’s focus on patient-centric innovations.
  • Growth Hormone Pens: These pens are part of the portfolio intended for patients requiring growth hormone therapy. They simplify the administration process, making treatment more accessible and manageable for patients.
  • Injection Needles: To complement their insulin and growth hormone pens, Novo Nordisk also supplies high-quality injection needles, designed for minimal discomfort and optimal medication delivery.
  • Smart Solutions for Diabetes: Innovating beyond conventional treatments, Novo Nordisk offers smart insulin pens and Dose Check, an insulin dose guidance application. These smart solutions enhance the treatment experience by integrating advanced technology with patient care, facilitating better management of diabetes.

Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.

Contact Information

Address: Novo Alle 1
Phone: 45 44 44 88 88